No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial

From OmniJournal
Revision as of 05:38, 22 July 2020 by Jtodaro2 (talk | contribs) (Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://www.medrxiv.org/content/10.1101/2020....")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Publication
Title
Authors
  • Matthieu Mahevas
  • Viet-Thi Tran
  • Mathilde Roumier
  • ...
  • Nathalie Costedoat
Journal medRxiv preprint
Date April 14, 2020

Non-randomized trial of 181 COVID-19 patients hospitalized for hypoxic pneumonia treated with hydroxychloroquine or standard therapy with primary endpoint of transfer to ICU. Of the patients treated with hydroxychloroquine, 20% also received azithromycin. There was no difference between treatment groups in transfer to ICU or death 7 days after hospital admission.

Based on C-reactive protein levels, most patients were already in a cytokine storm by the time treatment was initiated, which supported the theory that hydroxychloroquine is unlikely to be effective once patients are in a cytokine storm.

Major Issues

No major issues identified.

Minor Issues

No minor issues identified.

Impact

This study supported evidence that hydroxychloroquine has minimum to non-existent effects in late stage disease where patients are in cytokine storm.

Article Revisions

None at this time.

References